Tasly Pharmaceutical Group Co. Ltd. Class A

Tasly Pharmaceutical Group Co. Ltd. Class A

SSSE:600535
14.33
CNY
-0.06
(-0.42%)
0.77EPS
17.10P/E
20.92BMarket Cap
Mar 30Next Earn

Total Valuation

CNY

As of September 30, 2026, Tasly Pharmaceutical Group Co. Ltd. Class A carries a market capitalization of 20.92B, placing it among publicly traded companies globally. Its enterprise value stands at 17.52B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap20.92B
Enterprise Value17.52B

Important Dates

Tasly Pharmaceutical Group Co. Ltd. Class A's next confirmed earnings release is scheduled for March 30, 2027.

Earnings Date3/30/2027

Share Statistics

As of September 30, 2026, Tasly Pharmaceutical Group Co. Ltd. Class A has 1.49B shares outstanding.

Shares Outstanding1.49B

Valuation Ratios

As of September 30, 2026, Tasly Pharmaceutical Group Co. Ltd. Class A trades at a trailing price-to-earnings ratio of 17.10. The price-to-sales ratio is 2.61, and the price-to-book ratio stands at 1.62.

PE Ratio17.10
PS Ratio2.61
PB Ratio1.62
P/TBV Ratio1.92

Enterprise Valuation

As of September 30, 2026, Tasly Pharmaceutical Group Co. Ltd. Class A trades at an EV/EBITDA multiple of 11.88 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.19 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 11.88 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 17.52B versus a market cap of 20.92B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.19
EV / EBITDA11.88
EV / EBIT11.88

Financial Position

As of September 30, 2026, Tasly Pharmaceutical Group Co. Ltd. Class A maintains a current ratio of 4.86, meaning it holds 4.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.40, indicating moderate leverage, while an interest coverage ratio of 100.42 demonstrates strong ability to service its debt obligations.

Current Ratio4.86
Quick Ratio2.23
Debt / Equity1.40
Debt / EBITDA0.12
Interest Coverage100.42

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Tasly Pharmaceutical Group Co. Ltd. Class A posted a return on equity (ROE) of 9.67, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 8.39 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 8.02, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 9.46, useful for judging operating efficiency across full business cycles. The company generates approximately 757,309.09 in revenue per employee across its workforce of 10,563.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.74 indicates how many times Tasly Pharmaceutical Group Co. Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)9.67
Return on Assets (ROA)8.02
Return on Invested Capital (ROIC)8.39
Return on Capital Employed (ROCE)9.46
Revenue Per Employee757,309.09
Employee Count10,563.00
Inventory Turnover1.74

Taxes

CNY

Over the twelve months ended September 30, 2026, Tasly Pharmaceutical Group Co. Ltd. Class A recorded 307.72M in income tax expense. That works out to an effective tax rate of 21.03, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.46B, leaving 1.22B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax307.72M
Effective Tax Rate21.03

Stock Price Statistics

CNY

As of the close on November 17, 2026, Tasly Pharmaceutical Group Co. Ltd. Class A's stock has declined approximately 7.25% over the past 52 weeks. The 50-day moving average sits at 14.11, while the 200-day moving average is 14.50.

52-Week Price Change-7.25%
50-Day Moving Average14.11
200-Day Moving Average14.50

Income Statement

CNY

Over the twelve months ended September 30, 2026, Tasly Pharmaceutical Group Co. Ltd. Class A generated 8.00B in revenue and converted that into 1.22B in net income, yielding earnings per share of 0.77. EBITDA reached 1.48B, while operating income came in at 1.80B.

Revenue8.00B
Gross Profit5.44B
Operating Income1.80B
Pretax Income1.46B
Net Income1.22B
EBITDA1.48B
EBIT1.48B
Earnings Per Share (EPS)0.77

Balance Sheet

CNY

As of September 30, 2026, Tasly Pharmaceutical Group Co. Ltd. Class A holds 3.70B in cash and equivalents against 182.43M in total debt, resulting in a net debt position of -857.07M. Total book value stands at 12.92B, with working capital of 6.40B providing operational flexibility.

Cash & Cash Equivalents3.70B
Total Debt182.43M
Net Debt-857.07M
Equity (Book Value)12.92B
Book Value Per Share8.65
Working Capital6.40B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-350.15M

Margins

Over the twelve months ended September 30, 2026, Tasly Pharmaceutical Group Co. Ltd. Class A posted a gross margin of 68.00, reflecting its pricing power and cost economics. The operating margin of 22.49 and net profit margin of 15.29 provide insight into operational efficiency.

Gross Margin68.00
Operating Margin22.49
Pretax Margin18.30
Profit Margin15.29
EBITDA Margin18.44

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Tasly Pharmaceutical Group Co. Ltd. Class A paid dividends of 0.31 per share. The dividend payout ratio of 43.08 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 5.52, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Tasly Pharmaceutical Group Co. Ltd. Class A shareholders.

Dividend Per Share0.31
Payout Ratio43.08
Shareholder Yield5.52

Stock Splits

Tasly Pharmaceutical Group Co. Ltd. Class A's most recent stock split took place on June 5, 2018 with a 5:7 split ratio.

Last Split Date6/5/2018
Split Ratio5:7

Scores

As of September 30, 2026, Tasly Pharmaceutical Group Co. Ltd. Class A has an Altman Z-Score of 8.86, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score8.86